|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FCGR2A |
Gene summary for FCGR2A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FCGR2A | Gene ID | 2212 |
| Gene name | Fc fragment of IgG receptor IIa | |
| Gene Alias | CD32 | |
| Cytomap | 1q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | P12318 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2212 | FCGR2A | HCC1_Meng | Human | Liver | HCC | 7.80e-09 | 1.35e-02 | 0.0246 |
| 2212 | FCGR2A | Pt13.a | Human | Liver | HCC | 9.25e-04 | 2.55e-01 | 0.021 |
| 2212 | FCGR2A | Pt13.b | Human | Liver | HCC | 9.29e-03 | 8.13e-02 | 0.0251 |
| 2212 | FCGR2A | Pt13.c | Human | Liver | HCC | 1.00e-04 | 4.79e-01 | 0.0076 |
| 2212 | FCGR2A | Pt14.d | Human | Liver | HCC | 1.75e-14 | 5.07e-01 | 0.0143 |
| 2212 | FCGR2A | S028 | Human | Liver | HCC | 8.39e-04 | 2.92e-01 | 0.2503 |
| 2212 | FCGR2A | S029 | Human | Liver | HCC | 2.15e-05 | 5.49e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
| hsa0513042 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
| hsa0513542 | Liver | HCC | Yersinia infection | 92/4020 | 137/8465 | 2.25e-06 | 2.19e-05 | 1.22e-05 | 92 |
| hsa0414521 | Liver | HCC | Phagosome | 93/4020 | 152/8465 | 4.27e-04 | 1.88e-03 | 1.05e-03 | 93 |
| hsa0466610 | Liver | HCC | Fc gamma R-mediated phagocytosis | 58/4020 | 97/8465 | 9.65e-03 | 2.52e-02 | 1.40e-02 | 58 |
| hsa046112 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
| hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
| hsa0513052 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
| hsa0513552 | Liver | HCC | Yersinia infection | 92/4020 | 137/8465 | 2.25e-06 | 2.19e-05 | 1.22e-05 | 92 |
| hsa0414531 | Liver | HCC | Phagosome | 93/4020 | 152/8465 | 4.27e-04 | 1.88e-03 | 1.05e-03 | 93 |
| hsa0466611 | Liver | HCC | Fc gamma R-mediated phagocytosis | 58/4020 | 97/8465 | 9.65e-03 | 2.52e-02 | 1.40e-02 | 58 |
| hsa0461111 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FCGR2A | SNV | Missense_Mutation | c.170C>G | p.Ser57Cys | p.S57C | P12318 | protein_coding | tolerated(0.1) | benign(0.177) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FCGR2A | SNV | Missense_Mutation | c.845N>C | p.Glu282Ala | p.E282A | P12318 | protein_coding | tolerated(0.27) | benign(0.111) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FCGR2A | SNV | Missense_Mutation | novel | c.659T>G | p.Val220Gly | p.V220G | P12318 | protein_coding | tolerated(0.05) | possibly_damaging(0.503) | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| FCGR2A | insertion | Nonsense_Mutation | novel | c.394_395insTCCATTGTACAAAGAAATGCAACTGATTAGACCCAAG | p.Glu132ValfsTer9 | p.E132Vfs*9 | P12318 | protein_coding | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| FCGR2A | deletion | Frame_Shift_Del | novel | c.143delC | p.Pro48ArgfsTer11 | p.P48Rfs*11 | P12318 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| FCGR2A | SNV | Missense_Mutation | c.815G>T | p.Arg272Ile | p.R272I | P12318 | protein_coding | tolerated(0.19) | possibly_damaging(0.55) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FCGR2A | SNV | Missense_Mutation | c.489N>C | p.Gln163His | p.Q163H | P12318 | protein_coding | deleterious(0.03) | benign(0) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| FCGR2A | SNV | Missense_Mutation | c.489N>C | p.Gln163His | p.Q163H | P12318 | protein_coding | deleterious(0.03) | benign(0) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FCGR2A | SNV | Missense_Mutation | novel | c.717C>G | p.Ile239Met | p.I239M | P12318 | protein_coding | tolerated(0.06) | possibly_damaging(0.809) | TCGA-EA-A3QE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| FCGR2A | SNV | Missense_Mutation | rs750989159 | c.197N>A | p.Arg66His | p.R66H | P12318 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2212 | FCGR2A | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | infliximab | INFLIXIMAB | 25823785,24667440,24048425,27044681 | |
| 2212 | FCGR2A | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | adalimumab | ADALIMUMAB | 25823785,24667440,24048425,27044681 | |
| 2212 | FCGR2A | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | SM-101 | VALZIFLOCEPT | ||
| 2212 | FCGR2A | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | cetuximab | CETUXIMAB | 23296156,27897268,28719596,30318772 | |
| 2212 | FCGR2A | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | rituximab | RITUXIMAB | 30457672 | |
| 2212 | FCGR2A | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | trastuzumab | TRASTUZUMAB | 18347005,21109570 | |
| 2212 | FCGR2A | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | etanercept | ETANERCEPT | 24048425,27044681 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |